The Neat-HER virtual registry: Updated results on HER2+breast cancer patients receiving neratinib as extended adjuvant therapy.

被引：0
|
作者：
Vidal, Gregory A.
Tripathy, Debu
Hill, Nina
Lalla, Deepa
Hanson, Gillian
Drozd, Daniel R.
Xu, Feng
Rugo, Hope S.
机构：
[1] West Canc Ctr & Res Inst, Memphis, TN USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Calif San Francisco, Puma Biotechnol Inc, San Francisco, CA 94143 USA
[4] Puma Biotechnol Inc, Los Angeles, CA USA
[5] PicnicHealth, San Francisco, CA USA
[6] Univ Calif San Francisco, Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e13565
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13565
引用
收藏
页数：3
相关论文
共 50 条
  • [21] HER-2 therapy. HER-2/neu diagnostics in breast cancer
    Walter P Carney
    Kim Leitzel
    Suhail Ali
    Rainer Neumann
    Allan Lipton
    Breast Cancer Research, 9
  • [22] Adjuvant therapy of HER2+ breast cancer
    EP Winer
    Breast Cancer Research, 11
  • [23] Adjuvant therapy of HER2+ breast cancer
    Winer, E. P.
    BREAST CANCER RESEARCH, 2009, 11 : S6 - S6
  • [24] HER2-related biomarkers in HER2+breast cancer patients in Asia Pacific
    Kim, S-B
    Tsang, J.
    Kim, T-Y
    Yap, Y. S.
    Cornelio, G.
    Gong, G.
    Paik, S.
    Lee, S.
    Ng, T-Y
    Park, S.
    Oh, H-S
    Yau, T.
    Lee, S. H.
    Lim, J. H.
    Choi, Y-J
    Lee, E. M.
    Park, K-H
    Do, I-G
    Yeoh, E-M
    Ro, J.
    CANCER RESEARCH, 2013, 73
  • [25] Adjuvant trastuzumab and vinorelbine for early-stage HER2+breast cancer
    McLaughlin, Shannon
    Nakajima, Erika
    Bar, Yael
    Hutchinson, Jennifer A. A.
    Shin, Jennifer
    Moy, Beverly
    Isakoff, Steven J. J.
    Bardia, Aditya
    Kuter, Irene
    Spring, Laura M. M.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [26] Duration of extended adjuvant therapy with neratinib in early-stage HER2+breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial.
    Gnant, Michael
    Iwata, Hiroji
    Bashford, Anna Elizabeth
    Separovic, Robert
    Murias, Adolfo
    Vicente, Elena
    Means-Powell, Julie Ann
    Mayer, Ingrid A.
    Senecal, Francis Mark
    Hui, Rina
    De Boer, Richard H.
    Chiu, Joanne
    Armstrong, Anne
    Ruiz, Amparo
    Bryce, Richard
    Ye, Yining
    Chan, Arlene
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Adjuvant and neoadjuvant trastuzumab in combination with vinorelbine for HER2+breast cancer.
    Esfahani, Khashayar
    Ferrario, Cristiano
    Le, Philippe
    Panasci, Lawrence C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] TRASTUZUMAB INDUCED CARDIOTOXICITY IN PATIENTS WITH HER2+BREAST CANCER
    Santamaria Elena, Capilla
    Garcia Beatriz, Benitez
    Jose Antonio, Romero Garrido
    Aunon Pilar, Zamora
    Abad Gema, Casado
    del Valle Luis, Gonzalez
    Ambrosio Alicia, Herrero
    ATENCION FARMACEUTICA, 2013, 15 (04): : 261 - 267
  • [29] Assessing Neurohormonal in HER2+Breast Cancer Patients With CTRCD
    Albulushi, Arif
    Al-Farhan, Hatem
    JACC: CARDIOONCOLOGY, 2024, 6 (04): : 625 - 626
  • [30] Investigating the immune profile of early stage HER2+breast cancer patients receiving chemotherapy and HER2-targeted therapies
    Collins, Denis M.
    Gaynor, Nicola
    Madden, Stephen
    Toomey, Sinead
    Qiu, Ji
    Blayney, Jaine
    Blanco, Alfonso
    Fletcher, Jean
    Moran, Barry
    Kaukonen, Damien
    Ramirez, Javier Sanchez
    Kay, Elaine
    O'Connor, Darran
    Teiserskiene, Ausra
    Eustace, Alex
    Kennedy, Richard
    LaBaer, Joshua
    Gallagher, William
    Hennessy, Bryan
    Crown, John
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 487 - 487
12345